Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Targeted protein degradation has emerged as a novel therapeutic modality to treat human diseases by utilizing the cell's own disposal systems to remove protein target. Significant clinical benefits have been observed for degrading many intracellular proteins. Recently, the degradation of extracellular proteins in the lysosome has been developed. However, there have been limited successes in selectively degrading protein targets in disease-relevant cells or tissues, which would greatly enhance the development of precision medicine. Additionally, most degraders are not readily available due to their complexity. We report a class of easily accessible Folate Receptor TArgeting Chimeras (FRTACs) to recruit the folate receptor, primarily expressed on malignant cells, to degrade extracellular soluble and membrane cancer-related proteins in vitro and in vivo. Our results indicate that FRTAC is a general platform for developing more precise and effective chemical probes and therapeutics for the study and treatment of cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11461649 | PMC |
| http://dx.doi.org/10.1038/s41467-024-52685-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Folic acid conjugated magnetic chitosan nanocomposite for the targeted delivery of dual anticancer drugs to breast cancer and hyperthermia therapy.
Int J Biol Macromol
September 2025
Crystal Growth Centre, Anna University, Chennai, 600025, Tamil Nadu, India.
Increase in breast cancer has led to the search for systems that can enable, targeted, sustained and prolonged release of drugs while simultaneously reducing the side effects posed by them. In light of this, folic acid-conjugated 5-Fluorouracil and doxorubicin loaded chitosan/Fe₃O₄ (FA-dual@CS/Fe₃O₄) nanocomposite has been synthesized using the chemical method for targeted breast cancer therapy in addition to CS/FeO and dual drug encapsulated CS/FeO. FTIR and XPS studies confirm the successful drug encapsulation and FA conjugation.
View Article and Find Full Text PDFA novel treatment for diabetic nephropathy: Folate receptor-targeted delivery of TLR4 siRNA via functionalized PLGA nanoparticles in streptozotocin-induced diabetic murine models.
Nanomedicine
September 2025
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China; Department of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, Gansu, People's Republic of China; Key laboratory of nephropathy, The S
Diabetic kidney disease (DKD), a prominent microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease (ESRD), was addressed through a novel nanotherapeutic approach. This study engineered folic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles (FA-PLGA NPs) for the folate receptor (FR)-targeted delivery of Toll-like receptor 4 small interfering RNA (TLR4 siRNA) to treat diabetic nephropathy (DN). In a streptozotocin-induced DN murine model, administration of FA-PLGA NPs/TLR4 siRNA significantly mitigated renal injury compared to untreated DN controls.
View Article and Find Full Text PDFImportance: Effective and well-tolerated pharmacotherapies for generalized anxiety disorder (GAD), which is one of the most common psychiatric disorders, are needed.
Objective: To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD.
Design, Settings, And Participants: This phase 2b, multicenter, randomized, double-blind, placebo-controlled study enrolled 198 adults aged 18 to 74 years with a primary GAD diagnosis who presented with moderate to severe symptoms (defined by a Hamilton Anxiety Rating Scale [HAM-A] score ≥20) and was conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023.
A multifunctional oxidative stress amplifier for synergistic disruption of redox homeostasis and enhanced cancer therapy.
J Colloid Interface Sci
August 2025
College of Pharmacy, Key Laboratory of Innovative Drug Development and Evaluation, Hebei Medical University, Shijiazhuang, 050017, China; National Key Laboratory of New Pharmaceutical Preparations and Excipients, Hebei Medical University, Shijiazhuang 050017, China. Electronic address:
Emerging nanomedicines that target and disrupt redox homeostasis present a compelling yet technically demanding strategy for cancer therapy. Herein, a multifunctional oxidative stress amplifier, denoted as C-COF@MnO-BSA-FA/Ce6 (CMBFC), was engineered to disrupt redox homeostasis through synergistic mechanisms precisely. The nanoplatform was constructed with a core of N-doped carbon nanospheres derived from covalent organic frameworks (C-COF), which was then coated by an in situ mineralized MnO layer.
View Article and Find Full Text PDFStepwise targeting hyaluronic acid-based polymeric prodrug for acute kidney injury and prevents its progression to chronic kidney disease.
Mater Today Bio
October 2025
Department of Urology, The Affiliated LiHuiLi Hospital of Ningbo University, Ningbo, 315040, China.
Acute kidney injury (AKI) is characterized by a sudden decline in kidney function, often due to ischemia-reperfusion or nephrotoxic drugs. A key factor in AKI development is mitochondrial dysfunction, which disrupts energy and oxygen supply, increases ROS generation, and triggers inflammation. Addressing AKI through mitochondrial targeting remains challenging.
View Article and Find Full Text PDF